Yon-Dschun Ko

TL;DR: FGFR1 amplification is one of the most frequent therapeutically tractable genetic lesions in pulmonary carcinomas and might serve as a basis for identifying patients for ongoing and upcoming clinical trials.

TL;DR: Both KEAP1- and NFE2L2-mutated NSCLC patients represent a highly heterogeneous patient cohort, both are associated with different histologies and usually are found together with other cancer-related, partly targetable, genetic aberrations.

TL;DR: PIK3CA-mutated NSCLC represents a clinically and genetically heterogeneous subgroup in adenocarcinomas as well as in squamous cell carcinomas with a higher prevalence of these mutations in sqamous cell cancer.

TL;DR: The relative risks for breast cancer associated with the common susceptibility variants identified to date do not appear to vary across women with different reproductive histories or body mass index (BMI); the assumption of multiplicative combined effects for these established genetic and other risk factors in risk prediction models appears justified.